ARTICLE | Clinical News
Idelalisib regulatory update
February 10, 2014 8:00 AM UTC
Gilead disclosed on a conference call to discuss its 4Q13 and 2013 financial results that FDA accepted and granted Priority Review to an NDA for idelalisib to treat chronic lymphocytic leukemia (CLL)....